Objective: To assess the diagnostic performance of lateral flow immunochromatographic assays (LFAs) of 4 different manufacturers to identify SARS-CoV-2 antibodies (IgM, IgG, or total), c
(A) Melioidosis positive samples compared to healthy controls. (B) Melioidosis positive sera compared to bacteremia/fungemia positive samples. p values < 0.05 were considered significantly different b